appeared necessary and sufficient for Treg development 2 electrified investigators by providing the first specific marker identifying these enigmatic cells. T cells capable of inhibiting immune ...

the immune response subsides and long-lived memory versions of T cells and B cells are retained so that the appropriate response can be mounted much faster if the same germ is encountered again.

Vaccine is intended to stimulate T cell responses against targets across the entire genome of the selected virus, similar to company’s lead ...

In March 2025, Juventas Cell Therapy Ltd. conducted a phase Ib/II trial to evaluate the safety and efficacy of CNCT19 ...

A 63-year-old patient with multiple myeloma developed T cell lymphoma in the blood, skin and intestine nine months after undergoing CAR-T cell therapy at the University Hospital of Cologne.